Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86127 | 0.86 | CHRM2 (0.35) | CHRNA7 | |
| SCHEMBL85859 | 0.84 | CHRM2 (0.34) | — | |
| SCHEMBL18737180 | 0.82 | CHRM2 (0.33) | — | |
| SCHEMBL18737193 | 0.82 | CHRM2 (0.33) | — | |
| SCHEMBL18737181 | 0.82 | CHRM2 (0.33) | — | |
| SCHEMBL86171 | 0.82 | CHRM2 (0.33) | — | |
| SCHEMBL24930568 | 0.73 | — | — | |
| SCHEMBL15828399 | 0.70 | — | — | |
| SCHEMBL15828439 | 0.69 | — | — | |
| SCHEMBL15828400 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | CFD, CFH, C9 | CHRNA7 3485/4885GRM5 2416/4885 |
| US-20180022767-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | CHRNA7 3801/4885GRM5 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.